The benefit of EXtending oral antiCOAgulant treatment after acute Cerebral Vein Thrombosis (EX-COA -CVT) - EXCOA-CVT

niversity of Lisbon0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients with acute symptomatic and radiologically confirmed CVT ï?
•2.Age 18 years OR above at entry ï?
•3.CVT must have been diagnosed in less than 1 month before inclusion ï?
•4.The patient must be clinically stable and able to stop parenteral anticoagulation in order to initiate oral anticoagulation ï? ï?¡
•5.Written informed consent

•1.Systemic life-threatening or major bleeding while on anticoagulants during the acute phase of CVT or during the 6 months prior to randomisation (intracranial bleeding due to inclusion CVT is not an exclusion criteria) ï? ï?¡
•2.General contraindications for anticoagulant therapy ï?
•3.Need for prolonged treatment with antiplatelet drugs, non-steroidal anti-inflammatory drugs or other drugs/diseases that interferes significantly with anticoagulant therapy or with INR ï? ï?¡
•4.Life expectancy less than 2 years due to a pre-existing condition (including any malignancy) ï?
•5.Child bearing potential without adequate contraceptive measures, pregnancy or breast feeding ï?
•6.Known allergy to study medications ï?
•7.Other conditions judged by the investigator to be an absolute indication for prolonged oral anticoagulation
•such as recurrent CVT, VTE after CVT or first CVT with antiphospholipid syndrome or known severe
•thrombophilia (antithrombin, protein C or protein S deficiency, homozygous factor V Leiden or prothrombin G20210A mutation or combined abnormalities)

发起方

niversity of Lisbon